Gaucher Disease
Conditions
Keywords
Eliglustat
Brief summary
Primary Objective: Evaluate the efficacy and safety of eliglustat in Chinese pediatric patients (≥12 to \<18 years old) with Gaucher disease type 1 and type 3. Secondary Objective: Evaluate the quality of life in Chinese pediatric patients (≥12 to \<18 years old) with Gaucher disease type 1 and type 3 treated with eliglustat.
Interventions
DRUGEliglustat Tartrate Capsules
The initial dose is 42 mg taken orally twice a day. After 2 weeks of treatment, if the blood trough concentration is less than 5 ng/mL, the dose will be increased to 84 mg taken orally twice daily.
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* The patient is ≥12 to \<18 years old at the time of informed consent. * The patient is diagnosed with Gaucher disease based on the following criteria: 1. Glucocerebrosidase (GBA) activity reduced to ≤30% of the lower limit of normal, or 2. GBA activity reduced by \>30% of the lower limit of normal, but confirmed by glucocerebrosidase (GBA) genotype. * Postmenarchal female patients must have a documented negative pregnancy test prior to enrollment and throughout the study. * Patients must have been receiving enzyme replacement therapy (ERT) for a minimum of 24 months at a monthly dose equivalent to 30 U/kg to 130 U/kg of enzyme, with treatment ongoing at the time of enrollment. Patients must meet pre-specified treatment goals defined as: 1. Hemoglobin levels: ≥11.0 g/dL for females and ≥12.0 g/dL for males; 2. Platelet count ≥100,000/mm³; 3. Spleen volume \<10.0 multiples of normal (MN); 4. Liver volume \<1.5 MN. * After explaining and discussing all relevant aspects of the study with the patients and their guardians, patients and their guardians must voluntarily sign the written informed consent form approved by the institutional ethics committee. * Cytochrome P450 2D6 (CYP2D6) genotype testing shows extensive metabolizers (EMs) or intermediate metabolizers (IMs). * Patients agree to avoid consuming grapefruit and grapefruit juice. * Patients agree to discontinue medications listed as contraindicated for concomitant use. * Participants must be able to cooperate fully as determined by the Principal Investigator to be eligible for the study.
Exclusion criteria
* Underwent substrate reduction therapy (SRT) for GD or received miglustat treatment within 12 months prior to enrollment. * Underwent partial or total splenectomy prior to enrollment or experienced active, clinically significant splenic infarction within the previous 12 months. * The patient is transfusion-dependent; has a history of esophageal varices or liver infarction; elevated liver enzymes; significant congenital cardiac defect; coronary artery disease; left-sided heart failure; clinically significant arrhythmias; or conduction defects such as Type 2 second-degree or third-degree atrioventricular (AV) block, complete bundle branch block, prolonged QTc interval, or sustained ventricular tachycardia (VT). * Presence of significant comorbidities, as determined by the Principal Investigator, which may affect study data or confound study results (e.g., malignancies, primary biliary cirrhosis, autoimmune liver disease, pulmonary complications, cardiac structural or functional abnormalities, etc.). * The patient with any clinically significant disease other than GD. * Experienced severe bone disease such as new-onset bone crises or fractures within 12 months prior to enrollment. * The patient has received an investigational product within 30 days prior to enrollment. * The patient has a known hereditary galactose intolerance, Lapp lactase deficiency, glucose galactose malabsorption, or is a CYP2D6 ultra-rapid metabolizer or indeterminate metabolizer. * The patient is currently receiving erythropoiesis-stimulating agents (e.g., erythropoietin) or long-term systemic corticosteroid therapy, or received such treatment within 6 months prior to enrollment. * Positive hepatitis B surface antigen (HBsAg) test results with detectable hepatitis B virus DNA load; positive hepatitis C virus (HCV) antibody with confirmation by HCV RNA polymerase chain reaction (PCR) testing; and positive human immunodeficiency virus (HIV) antibody at screening. * Presence of non-GD-related hemolytic anemia (such as due to iron, folate, and/or vitamin B12 deficiency or infection/immune-mediated causes) at screening. Patients with folate deficiency, vitamin B12 deficiency-related anemia, or iron deficiency-related anemia at screening are ineligible for study enrollment and will be considered screening failures. Patients may receive treatment for underlying conditions and be re-screened at the discretion of the Principal Investigator. * The patient and their guardian are unable to comprehend the nature, scope, and potential consequences of the study. * The Principal Investigator determines that the patient is unsuitable for participation in the clinical trial based on the subject's overall condition.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of pharmacokinetic (PK) parameter of eliglustat: Ctrough | Baseline, Weeks 2, 13, 26 and 52 | Trough concentration (Ctrough) of eliglustat in plasma (ng/mL) |
| Adverse events | Up to Week 52 | Number of adverse events in pediatric patients |
| Changes in hemoglobin level | Baseline, Weeks 13, 26, 39 and 52 | Absolute change from baseline for hemoglobin (g/dL) |
| Changes in platelet count | Baseline, Weeks 13, 26, 39 and 52 | Percent change from baseline for platelet count |
| Changes in spleen volume | Baseline, Weeks 26 and 52 | Percent change from baseline for spleen volume |
| Changes in liver volume | Baseline, Weeks 26 and 52 | Percent change from baseline for liver volume |
| Changes in Lyso-GL1 level | Baseline, Weeks 13, 26, 39 and 52 | Percent change from baseline for Lyso-GL1 level |
| Skeletal improvement | Baseline, Weeks 26 and 52 | Proportion of patients with improvement in skeletal disease |
| Assessment of pharmacokinetic (PK) parameter of eliglustat: Cmax | Baseline, Weeks 2, 13, 26 and 52 | Peak concentration (Cmax) of eliglustat in plasma (ng/mL) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Quality of Life | Baseline and Week 52 | Health-related quality of life will be measured by the Pediatric Quality of Life Inventory™ (PedsQL™) questionnaires |
Countries
China
Contacts
Primary ContactBing Han
Backup ContactLeyu Wang
Outcome results
None listed